Analysts Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $25.60

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have been given an average rating of “Buy” by the six brokerages that are presently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $25.60.

ATXS has been the topic of several analyst reports. Oppenheimer raised their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a research report on Monday, January 13th.

Institutional Investors Weigh In On Astria Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers boosted its stake in Astria Therapeutics by 4.1% during the 2nd quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company’s stock valued at $595,000 after purchasing an additional 2,556 shares in the last quarter. Quest Partners LLC boosted its stake in Astria Therapeutics by 3,310.6% during the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 3,112 shares in the last quarter. SG Americas Securities LLC grew its holdings in Astria Therapeutics by 51.3% during the fourth quarter. SG Americas Securities LLC now owns 21,296 shares of the biotechnology company’s stock worth $190,000 after acquiring an additional 7,218 shares during the period. Bank of New York Mellon Corp raised its position in Astria Therapeutics by 6.9% in the second quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company’s stock worth $1,266,000 after acquiring an additional 8,965 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in Astria Therapeutics by 8.7% in the third quarter. Wellington Management Group LLP now owns 147,499 shares of the biotechnology company’s stock worth $1,624,000 after acquiring an additional 11,763 shares in the last quarter. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Stock Performance

Astria Therapeutics stock opened at $7.50 on Monday. The firm has a market capitalization of $423.23 million, a P/E ratio of -3.59 and a beta of 0.70. The company has a 50-day simple moving average of $9.43 and a 200-day simple moving average of $10.64. Astria Therapeutics has a one year low of $6.95 and a one year high of $16.90.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.